Evidence map›Paper›PMID 27253419›Full record

ArticleScientific reports2016

14-3-3γ Prevents Centrosome Amplification and Neoplastic Progression.

Amitabha Mukhopadhyay, Lalit Sehgal, Arunabha Bose, Anushree Gulvady, Parijat Senapati, Rahul Thorat, Srikanta Basu, Khyati Bhatt, Amol S Hosing, Renu Balyan and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. NPM1 Biology in Myeloid Neoplasia.Current hematologic malignancy reports · 2020
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Amitabha MukhopadhyayAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Lalit SehgalAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Arunabha BoseAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Anushree GulvadyAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Parijat SenapatiTranscription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India.
Rahul ThoratAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Srikanta BasuAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Khyati BhattAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Amol S HosingAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Renu BalyanNational Institute of Immunology, New Delhi 110067, India.
Lalit BordeDepartment of Biological Sciences, Tata Institute of Fundamental Research, Mumbai 400005, India.
Tapas K KunduTranscription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India.
Sorab N DalalAdvanced Centre for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai 410210, India.
Advanced Centre for Treatment, Research and Education in Cancer · INJawaharlal Nehru Centre for Advanced Scientific Research · INNational Institute of Immunology · INTata Institute of Fundamental Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than 80% of malignant tumors show centrosome amplification and clustering. Centrosome amplification results from aberrations in the centrosome duplication cycle, which is strictly coordinated with DNA-replication-cycle. However, the relationship between cell-cycle regulators and centrosome duplicating factors is not well understood. This report demonstrates that 14-3-3γ localizes to the centrosome and 14-3-3γ loss leads to centrosome amplification. Loss of 14-3-3γ results in the phosphorylation of NPM1 at Thr-199, causing early centriole disjunction and centrosome hyper-duplication. The centrosome amplification led to aneuploidy and increased tumor formation in mice. Importantly, an increase in passage of the 14-3-3γ-knockdown cells led to an increase in the number of cells containing clustered centrosomes leading to the generation of pseudo-bipolar spindles. The increase in pseudo-bipolar spindles was reversed and an increase in the number of multi-polar spindles was observed upon expression of a constitutively active 14-3-3-binding-defective-mutant of cdc25C (S216A) in the 14-3-3γ knockdown cells. The increase in multi-polar spindle formation was associated with decreased cell viability and a decrease in tumor growth. Our findings uncover the molecular basis of regulation of centrosome duplication by 14-3-3γ and inhibition of tumor growth by premature activation of the mitotic program and the disruption of centrosome clustering.

Indexed as

Chromosomal Instability14-3-3 ProteinsAneuploidyAnimalscdc25 PhosphatasesCell CycleCell Line, TumorCentrosomeGene DeletionHCT116 CellsHumansMiceNeoplasmsNeoplasm TransplantationNuclear ProteinsNucleophosmin14-3-3 ProteinsCdc25c protein, mousecdc25 PhosphatasesNPM1 protein, humanNpm1 protein, mouseNuclear ProteinsNucleophosminThreonine

Identifiers

PMID27253419
PMCPMC4890593
OpenAlexW2409238004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.